UroGen Pharma Ltd [NASDAQ: URGN] slipped around -0.25 points on Friday, while shares priced at $10.27 at the close of the session, down -2.38%.
Compared to the average trading volume of 449.47K shares, URGN reached a trading volume of 262698 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about UroGen Pharma Ltd [URGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for URGN shares is $39.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on URGN stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for UroGen Pharma Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 22, 2024. While these analysts kept the previous recommendation, Jefferies dropped their target price from $35 to $10. The new note on the price target was released on February 08, 2023, representing the official price target for UroGen Pharma Ltd stock. Previously, the target price had yet another raise to $20, while Berenberg analysts kept a Buy rating on URGN stock. On April 16, 2020, analysts increased their price target for URGN shares from 53 to 57.
The Average True Range (ATR) for UroGen Pharma Ltd is set at 0.61, with the Price to Sales ratio for URGN stock in the period of the last 12 months amounting to 4.85. The Price to Book ratio for the last quarter was 16.98, with the Price to Cash per share for the same quarter was set at 5.94.
How has URGN stock performed recently?
UroGen Pharma Ltd [URGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.29. With this latest performance, URGN shares dropped by -9.12% in over the last four-week period, additionally sinking by -38.28% over the last 6 months – not to mention a drop of -34.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for URGN stock in for the last two-week period is set at 39.53, with the RSI for the last a single of trading hit 39.69, and the three-weeks RSI is set at 40.01 for UroGen Pharma Ltd [URGN]. The present Moving Average for the last 50 days of trading for this stock 11.46, while it was recorded at 10.26 for the last single week of trading, and 13.50 for the last 200 days.
UroGen Pharma Ltd [URGN]: Deeper insight into the fundamentals
UroGen Pharma Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.77 and a Current Ratio set at 9.00.
Insider trade positions for UroGen Pharma Ltd [URGN]
There are presently around $92.24%, or 101.56%% of URGN stock, in the hands of institutional investors. The top three institutional holders of URGN stocks are: RTW INVESTMENTS, LP with ownership of 3.56 million shares, which is approximately 10.6572%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 3.3 million shares of the stock with an approximate value of $$55.37 million in URGN stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$51.74 million in URGN stock with ownership which is approximately 9.2374%.
